Haartmaninkatu 8 (PO Box 63)
00014 University of Helsinki
Phone: +358 2941 25555
E-mail: liisa.kauppi@helsinki.fi
My research focuses on DNA damage repair, especially homologous recombination (HR) repair, in high-grade serous ovarian cancer (HGSOC). In our lab, we have established an immunofluorescence-based assay to detect HR deficiency in HGSOC tumor cells. By utilizing this assay, my aim is to find a way to (re-)sensitize cancer cells to chemotherapy by manipulating HR repair pathway.
E-mail: sanna.pikkusaari@helsinki.fi
LINE-1 are transposable elements that comprise approximately 17% of human DNA. Even though silent in normal cells, LINE-1s are transcriptionally active in different types of cancer, often resulting in de novo insertions and therefore conducting to genomic instability. I am interested to understand the genomic evolution of LINE-1 activity in high-grade serous ovarian cancer.
E-mail: fatih.genc@helsinki.fi
There is recent, mounting evidence that bacteria and viruses play a previously unappreciated role in cancer development and response to therapy. Microbiota encompasses a wide variety of microorganisms (bacteria, viruses, fungi) and has gathered increasing attention regarding their role in carcinogenesis. Our objective is to provide a new perspective into the molecular behavior of high-grade serous ovarian carcinoma (HGSOC), by studying the presence and role of bacteria and viruses in causing DNA damage, and to present novel target treatments aimed towards bacteria and viruses to improve the clinical outcome of this disease.
E-mail: oussama.kramisenhaji@helsinki.fi
Project: Targeting CCNE1 Amplification in HGSOC
Centered on high-grade serous ovarian cancer (HGSOC), my research is rooted in the pivotal role of DNA damage and its targeted treatments. My research aims to tackle CCNE1 amplification in HGSOC, a genetic alteration present in at least 20% of the HGSOC patients. My dedication centers on understanding the molecular intricacies underlying CCNE1 amplification and its impact on HGSOC progression. Given that existing therapies are efficient solely in HR-deficient tumors, I aim to delve into synthetic lethality approaches specifically tailored for HR-proficient tumor cells harboring CCNE1 amplification.
E-mail: anu.anil@helsinki.fi
The goal of my project is to understand the temporal location of the DNA damage (% in S phase), the differences in the tumour microenvironment (TME) between HR-deficient and HR-proficient tumours and propose avenues for alternative treatment strategies.
E-mail: srividhya.sundaresan@helsinki.fi
My current project aims to investigate the effect of pre-fixation time on functional testing of HR (homologous recombination), using various fixation time points on samples obtained from Primary Debulking Surgery (PDS). Additionally, the research seeks to explore whether time-to-fixation extends its influence to other predictive and diagnostic tests.
E-mail: ezgi.karagoz@helsinki.fi
E-mail: minna.eriksson@helsinki.fi
Phone: 0504489442
A knock-out mouse model (Dnah3-/-) previously generated in the lab displays sperm immotility and consequently also male infertility. In my project, I use FinnGen data to see if genomic variants in the Dnah3 gene also lead to infertility and/or subfertility in Finnish men. Moreover, I analyze FinnGen DNA sequence data from men with the appropriate phenotypes and then compare this data to healthy controls.
E-mail: filippa.tallqvist@helsinki.fi
Post-doctoral researcher
Miia Kaistamaa, MD
Kul Shrestha, PhD
Manuela Tumiati, PhD
Nanna Sarvilinna, PhD
Imrul Faisal, PhD
Linlin Zhang, MD, PhD
Susanna Jonkka, MSc
Denis Dermadi Bebek, PhD
Vanessa Keser, ERASMUS student
Venkatram Yellapragada, MSc
Martyna Salciute, BSc
Elli Aska, PhD
Jasmin Grönman, MSc
Juha Matilainen, PhD
Barun Pradhan, post-doc
Henrik Talsi, summer student
Oona Mehtälä, summer student
Maarit Hakkarainen, lab technician
Taina Turunen, lab technician
Minna Tuominen, lab manager
Saundarya Shah, lab manager